Economic evaluation of HBV vaccination: A systematic review of recent publications (2000–2013)

References

• Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 (Suppl 4):5-13; PMID:21115576; http://dx.doi.org/10.1634/theoncologist.2010-S4-05
   PubMed Web of Science ®Google Scholar
• WHO. Revised WHO position paper on hepatitis B vaccine, Oct 2009 – the abridged version - (draft 22 Sept 2009). Available from: http://www.who.int/immunization/HepB_position_paper_oct09_summary.pdf
   Google Scholar
• Drummond MF. Principles of economic appraisal in health care Oxford University Press, Oxford, 1980
   Google Scholar
• Lahaye D, Strauss P, Baleux C, van Ganse W. Cost-benefit analysis of hepatitis-B vaccination. Lancet 1987; 2(8556):441-3; PMID:2887738; http://dx.doi.org/10.1016/S0140-6736(87)90971-8
   PubMed Web of Science ®Google Scholar
• Liguori G, Gallé F, Marinelli P. Epidemiology of hepatitis C virus infection in the world, Europe, Italy and Campania: an overview. Ital J Public Health 2004; 1(1–2):40-6
   Google Scholar
• WHO. Hepatitis B (Fact sheet N°204). Available from: http://www.who.int/mediacentre/factsheets/fs204/en/ (updated July 2013)
   Google Scholar
• Di Giuseppe G, Nobile CG, Marinelli P, Angelillo IF. A survey of knowledge, attitudes, and behavior of Italian dentists toward immunization. Vaccine 2007; 25(9):1669-75; PMID:17129642; http://dx.doi.org/10.1016/j.vaccine.2006.10.056
   PubMed Web of Science ®Google Scholar
• Piazza M. Experimental Viral Hepatitis. Charles C. Thomas Pubbl. Illinois, 1969
   Google Scholar
• Piazza M, Guadagnino V, Picciotto L, Borgia G, Nappa S. Contamination by hepatitis B surface antigen in dental surgeries. Br Med J (Clin Res Ed). 1987 Aug 22; 295(6596):473-4; PMID:3117175
   PubMedGoogle Scholar
• Piazza M. Universal hepatitis B vaccination. Lancet Infect Dis 2008 Feb; 8(2):88-9; PMID:18222158; http://dx.doi.org/10.1016/S1473-3099(08)70005-7
   PubMed Web of Science ®Google Scholar
• Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ 2001; 10(8):751-74; PMID:11747055; http://dx.doi.org/10.1002/hec.625
   PubMed Web of Science ®Google Scholar
• Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ. Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev Vaccines 2009; 8(7):907-20; PMID:19538116; http://dx.doi.org/10.1586/erv.09.53
   PubMed Web of Science ®Google Scholar
• Zhang W, Guo Z, Zhang L, Liu Z, Li J, Ji Z, Xu R, Zhao N, Li F, Chen X, et al. Maternal immunization promotes the immune response of neonates towards hepatitis B vaccine. J Viral Hepat 2013 Dec; 20(12):875-81; PMID:24304457; http://dx.doi.org/10.1111/jvh.12103
   PubMed Web of Science ®Google Scholar
• Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology 2010; 53(1):20-8; PMID:20068337; http://dx.doi.org/10.1159/000252780
   PubMed Web of Science ®Google Scholar
• Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 2012 Feb; 16(2):e82-8; PMID:22178658; http://dx.doi.org/10.1016/j.ijid.2011.10.009
   PubMed Web of Science ®Google Scholar
• Mao B, Patel MK, Hennessey K, Duncan RJ, Wannemuehler K, Soeung SC. Prevalence of chronic hepatitis B virus infection after implementation of a hepatitis B vaccination program among children in three provinces in Cambodia. Vaccine 2013Sep 13; 31(40):4459-64; PMID:23684825; http://dx.doi.org/10.1016/j.vaccine.2013.05.009
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Vu MH, Nguyen VC, Nguyen LH, Toda K, Nguyen TN, Dao S, Wannemuehler KA, Hennessey KA. A reduction in chronic hepatitis B virus infection prevalence among children in Vietnam demonstrates the importance of vaccination. Vaccine 2013; 32(2):217-22
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis B (Fact sheet N°204). Available from: http://www.who.int/mediacentre/factsheets/fs204/en/ (updated July 2013)
   Google Scholar
• CDC. Global Routine Vaccination Coverage, 2011. Morbidity and Mortality Weekly Report (MMWR) 2012; 61(43):883-885
   PubMedGoogle Scholar
• Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993; 118(4):298-306; PMID:8420448; http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00009
   PubMed Web of Science ®Google Scholar
• Holliday SM, Faulds D. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. Pharmacoeconomics 1994; 5(2):141-71; PMID:10146907; http://dx.doi.org/10.2165/00019053-199405020-00008
   PubMed Web of Science ®Google Scholar
• Antoñanzas F, Garuz R, Rovira J, Antón F, Trinxet C, Navas E, Salleras L. Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain. Pharmacoeconomics 1995; 7(5):428-43; http://dx.doi.org/10.2165/00019053-199507050-00007
   PubMed Web of Science ®Google Scholar
• Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274:1202-9; http://dx.doi.org/10.1001/jama.1995.03530150025029
   Web of Science ®Google Scholar
• Van Damme P, Tormans G, Beutels P, Van Doorslaer E. Hepatitis B prevention in Europe: a preliminary economic evaluation. Vaccine 1995; 13(S1):54-7; PMID:7762278; http://dx.doi.org/10.1016/0264-410X(95)80053-G
   PubMed Web of Science ®Google Scholar
• Hicks RA, Cullen JW, Jackson MA, Burry VF. Hepatitis B virus vaccine. Cost-benefit analysis of its use in a children's hospital. Clin Pediatr (Phila) 1989; 28(8):359-65; PMID:2527103; http://dx.doi.org/10.1177/000992288902800805
   PubMed Web of Science ®Google Scholar
• Edmunds W, Dejene A, Mekonnen Y, Haile M, Alemnu W, Nokes D. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy Plan 2000; 15(4):408-16; PMID:11124244; http://dx.doi.org/10.1093/heapol/15.4.408
   PubMed Web of Science ®Google Scholar
• Fernández Barboza R, Rivero D, Echeverría B, Machado IV. Cost-benefits of vaccination against hepatitis B in hospital personnel in Venezuela. Bol Oficina Sanit Panam 1991; 111(1):16-23
   PubMedGoogle Scholar
• Hatziandreu EJ, Hatzakis A, Hatziyannis S, Kane MA, Weinstein MC. Cost-effectiveness of hepatitis-B vaccine in Greece. A country of intermediate HBV endemicity. Int J Technol Assess Health Care 1991; 7(3):256-62; PMID:1834601; http://dx.doi.org/10.1017/S026646230000564X
   PubMedGoogle Scholar
• Pennie RA, O'Connor AM, Dulberg CS, Bottiglia A, Manga P, Kang CY. Low-cost hepatitis B vaccine improves uptake among self-paying health-care students. J Med Virol 1992; 37(1):48-53; PMID:1535653; http://dx.doi.org/10.1002/jmv.1890370108
   PubMed Web of Science ®Google Scholar
• La Torre G, Saulle R, Unim B. Hepatitis B immunization in health care workers: needs and opportunities. Hepatitis Monthly 2011; 11(8):664-5; PMID:22140393; http://dx.doi.org/10.5812/kowsar.1735143X.1504
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Di Filippo S, Marcelli D, Guarnori I, Raffaele L, Crepaldi M, Erba G, Locatelli F. Recombinant hepatitis B vaccine use in chronic hemodialysis patients. Long-term evaluation and cost-effectiveness analysis. Nephron 1996; 72(4):536-43; PMID:8730417; http://dx.doi.org/10.1159/000188935
   PubMed Web of Science ®Google Scholar
• La Torre G, De Vito E, Langiano E, Petta P, Colarossi G, Cipriani L, Tucciarone M, Ricciardi G. Epidemiology of hepatitis C virus antibodies in blood donors from the province of Latina, Italy. Eur J Epidemiol 2003; 18(7):691-4; PMID:12952144; http://dx.doi.org/10.1023/A:1024817417635
   PubMed Web of Science ®Google Scholar
• Da Villa G, Sepe G. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness. Vaccine 1999; 17:1734-8; PMID:10194831; http://dx.doi.org/10.1016/S0264-410X(98)00414-9
   PubMed Web of Science ®Google Scholar
• La Torre G, Nicolotti N, de Waure C, Chiaradia G, Specchia ML, Mannocci A, Ricciardi W. An assessment of the effect of hepatitis B vaccine in decreasing the amount of hepatitis B disease in Italy. Virology J 2008; 5:84; http://dx.doi.org/10.1186/1743-422X-5-84
   PubMed Web of Science ®Google Scholar
• Wiewióra-Pilecka D. Cost-benefit analysis of the Polish hepatitis B prevention Programme. Vaccine 2000; 18:S52-4; http://dx.doi.org/10.1016/S0264-410X(99)00465-X
   PubMed Web of Science ®Google Scholar
• Harris A, Yong K, Kermode M. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness. Aust N Z J Public Health 2001; 25(3):222-9; PMID:11494989; http://dx.doi.org/10.1111/j.1467-842X.2001.tb00566.x
   PubMed Web of Science ®Google Scholar
• Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol 2001; 16:301-8; PMID:11339422; http://dx.doi.org/10.1046/j.1440-1746.2001.02443.x
   PubMed Web of Science ®Google Scholar
• Saab S, Weston SR, Ly D, Brezina M, Yee HF, Jr, Han SH, Gitnick G. Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patients. Vaccine 2002; 20(25–26):3230-5; PMID:12163275; http://dx.doi.org/10.1016/S0264-410X(02)00249-9
   PubMed Web of Science ®Google Scholar
• Adibi P, Rezailashkajani M, Roshandel D, Behrouz N, Ansari S, Somi MH, Shahraz S, Zali MR. An economic analysis of premarriage prevention of hepatitis B transmission in Iran. BMC Infect Dis 2004 Sep 4; 4:31; PMID:15347430; http://dx.doi.org/10.1186/1471-2334-4-31
   PubMed Web of Science ®Google Scholar
• Vimolket T, Poovorawan Y. An economic evaluation of universal infant Vaccination strategies against Hepatitis B in Thailand: an analytic decision approach to Cost-effectiveness. Southeast Asian J Trop Med Public health 2005; 36(3):693-9; PMID:16124440
   PubMedGoogle Scholar
• Kim SY, Billah K, Lieu TA, Weinstein MC. Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med 2006; 30(6):498-506; PMID:16704944; http://dx.doi.org/10.1016/j.amepre.2006.01.017
   PubMed Web of Science ®Google Scholar
• Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007; 147(7):460-9; PMID:17909207; http://dx.doi.org/10.7326/0003-4819-147-7-200710020-00004
   PubMed Web of Science ®Google Scholar
• Jakiche R, Borrego ME, Raisch DW, Gupchup GV, Pai MA, Jakiche A. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses. Am J Med Sci 2007; 333(1):26-34; PMID:17220691; http://dx.doi.org/10.1097/00000441-200701000-00004
   PubMed Web of Science ®Google Scholar
• Tilson L, Thornton L, O'Flanagan D, Johnson H, Barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health 2007; 18(3):275-82; PMID:18160389; http://dx.doi.org/10.1093/eurpub/ckm123
   PubMed Web of Science ®Google Scholar
• Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, Heimer R. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med 2008; 35(1):25-32; PMID:18541174; http://dx.doi.org/10.1016/j.amepre.2008.03.028
   PubMed Web of Science ®Google Scholar
• Miriti MK, Billah K, Weinbaum C, Subiadur J, Zimmerman R, Murray P, Gunn R, Buffington J. Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the US. Public Health Rep 2008; 123(4):504-13; PMID:18763413
   PubMed Web of Science ®Google Scholar
• Hung HF, Chen THH. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: An experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence. Vaccine 2009; 27:6770-6; PMID:19735755; http://dx.doi.org/10.1016/j.vaccine.2009.08.082
   PubMed Web of Science ®Google Scholar
• Fischinger JM, Stephan B, Wasserscheid K, Eichler H, Gärtner BC. A cost-benefit analysis of blood donor vaccination as an alternative to additional DNA testing for reducing transfusion transmission of hepatitis B virus. Vaccine 2010; 28(49):7797-802; PMID:20875488; http://dx.doi.org/10.1016/j.vaccine.2010.09.037
   PubMed Web of Science ®Google Scholar
• Siddiqui MR, Gay N, Edmunds WJ, Ramsay M. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine 2011; 29(3):466-75; PMID:21073988; http://dx.doi.org/10.1016/j.vaccine.2010.10.075
   PubMed Web of Science ®Google Scholar
• Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine 2012; 31(1):252-9; PMID:22902676; http://dx.doi.org/10.1016/j.vaccine.2012.08.007
   PubMed Web of Science ®Google Scholar
• Savova A, Petrova G, Gotseva A, Kurcatova A, Koguharova M. Economic analysis 20 years after the introduction of universal HBV immunisation in Bulgaria. Biotechnol Biotechnol Eq 2012; 26(1):2811-6; http://dx.doi.org/10.5504/BBEQ.2011.0141
   Web of Science ®Google Scholar
• Tu HAT, de Vries R, Woerdenbag HJ, Li SC, Le HH, van Hulst M, Postma MJ. Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost-Effectiveness Affordability Curves in Health Care Decision Making. Value in Health Regional Issues 2012; 1:7-14; http://dx.doi.org/10.1016/j.vhri.2012.03.007
   PubMedGoogle Scholar
• Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics 2013; 131(4):e1135-43; PMID:23530168; http://dx.doi.org/10.1542/peds.2012-1262
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Schillie S, Wittenborn JS, Bradley CL, Zhou F, Byrd K, Murphy TV. Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes. Diabetes Care 2013; 36(1):63-9; PMID:22933435; http://dx.doi.org/10.2337/dc12-0759
   PubMed Web of Science ®Google Scholar
• Kuan RK, Janssen R, Heyward W, Bennett S, Nordyke R. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B→ vaccine. Vaccine 2013; 31(37):4024-32; PMID:23707166; http://dx.doi.org/10.1016/j.vaccine.2013.05.014
   PubMed Web of Science ®Google Scholar
• Lu SQ, McGhee SM, Xie X, Cheng J, Fielding R. Economic evaluation of universal newborn hepatitis B vaccination in China. Vaccine 2013; 31(14):1864-9; PMID:23384752; http://dx.doi.org/10.1016/j.vaccine.2013.01.020
   PubMed Web of Science ®Google Scholar
• La Torre G, Vezzo D, Arcese R, Bongiovanni C, Capelli G, Ricciardi G. Occurrence and correlates of HIV and Hepatitis B/C virus infections among prisoners of Southern Lazio, Italy. Ital J Public Health 2004; 1:33-9
   Google Scholar
• SeyedAlinaghi SA, Kheirandish P, Karami N, Salem S, Shirzad H, Jahani MR, SeyedAhmadian MR, Valiollahi P, Hosseini M, Mohraz M, McFarland W. High prevalence of chronic hepatitis B infection among injection drug users in Iran: the need to increase vaccination of adults at risk. Acta Med Iran 2010 Jan–Feb; 48(1):58-60; PMID:21137671
   PubMedGoogle Scholar
• Hwang LY, Grimes CZ, Tran TQ, Clark A, Xia R, Lai D, Troisi C, Williams M. Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. J Infect Dis 2010 Nov 15; 202(10):1500-9; PMID:20936979; http://dx.doi.org/10.1086/656776
   PubMed Web of Science ®Google Scholar
• Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of Immunogenicity and Safety of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: A Randomized, Controlled Trial. PLoS One 2013 Nov 12; 8(11):e80409; PMID:24265819; http://dx.doi.org/10.1371/journal.pone.0080409
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011 Dec 23; 60(50):1709-11; PMID:22189894
   PubMedGoogle Scholar
• Simani OE, Leroux-Roels G, François G, Burnett RJ, Meheus A, Mphahlele MJ. Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic. Vaccine 2009 Jan 1; 27(1):146-51; PMID:18940220; http://dx.doi.org/10.1016/j.vaccine.2008.10.004
   PubMed Web of Science ®Google Scholar
• Hodgson A, Forgor AA, Chandramohan D, Reed Z, Binka F, Bevilacqua C, Boutriau D, Greenwood B. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS One 2008 May 14; 3(5):e2159; PMID:18478093; http://dx.doi.org/10.1371/journal.pone.0002159
   PubMed Web of Science ®Google Scholar
• Montesano R. Hepatitis B immunization and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study. J Med Virol 2002 Jul; 67(3):444-6; PMID:12116042; http://dx.doi.org/10.1002/jmv.10093
   PubMed Web of Science ®Google Scholar
• Whittle HC, Maine N, Pilkington J, Mendy M, Fortuin M, Bunn J, Allison L, Howard C, Hall A. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995 Apr 29; 345(8957):1089-92; PMID:7715343; http://dx.doi.org/10.1016/S0140-6736(95)90822-6
   PubMed Web of Science ®Google Scholar
• Excler JL, Yvonnet B, Gaye Y, Monnereau A, Mangin JL, Schlumberger M, Mireux F, Gaye AB, Sarr LC. Inclusion of hepatitis B vaccination in the Expanded Program of Immunization: feasibility study in the medical region of Kolda (Senegal). Sante 1995 Jan–Feb; 5(1):37-42; PMID:7894828
   PubMedGoogle Scholar
• Coursaget P, Deciron F, Tortey E, Barin F, Chiron JP, Yvonnet B, Diouf C, Denis F, Diop-Mar I, Correa P, et al. Immune response to hepatitis B vaccine in infants and newborns: control trial in an endemic area (Senegal). IARC Sci Publ 1984; (63):319-35; PMID:6242150
   PubMedGoogle Scholar
• Espinoza F, Tregnaghi M, Gentile A, Abarca K, Casellas J, Collard A, Lefevre I, Jacquet JM. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial. BMC Infect Dis 2010 Oct 15; 10:297; PMID:20950456; http://dx.doi.org/10.1186/1471-2334-10-297
   PubMed Web of Science ®Google Scholar
• Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, de Schryver A, Reynders D, Connell J, Gerlich WH, et al. European Consensus Group. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 2003 Aug; 27(3):213-30; PMID:12878084; http://dx.doi.org/10.1016/S1386-6532(03)00087-8
   PubMed Web of Science ®Google Scholar
• Roman∫ L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig Liver Dis 2011; 43 Suppl 1:S2-7; http://dx.doi.org/10.1016/S1590-8658(10)60685-8
   PubMedGoogle Scholar
• Teshale EH, Hepatitis B. In Centers For Disease Control and Prevention. CDC Health InFormation For International Travel 2012, OxfordUniversity Press, NewYork, NY, USA, 2012, available at http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-b.htm
   Google Scholar
• Garnett GP. The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease. Vaccine 2014 Mar 20; 32(14):1536-42; PMID:24606635; http://dx.doi.org/10.1016/j.vaccine.2013.11.007
   PubMed Web of Science ®Google Scholar
• Ieluzzi D, Covolo L, Donato F, Fattovich G. Progression to cirrhosis, hepatocellular carcinoma and liver-related mortality in chronic hepatitis B patients in Italy. Dig Liver Dis 2014; 46(5):427-32; PMID:24548819
   PubMedGoogle Scholar
• International Agency for Research on Cancer. Biological agents. Volume 100B. A review of human carcinogens. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, pp. 93-133, World Health Organization, Geneva, Switzerland, 2012, available at http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php
   Google Scholar
• World Health Organization. “Viral hepatitis. Report by the secretariat,” in Proceedings of the 63rd World Health Assembly March 2010
   Google Scholar
• Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18 Suppl 1:1-16; PMID:21824223; http://dx.doi.org/10.1111/j.1365-2893.2011.01499.x
   PubMed Web of Science ®Google Scholar
• Franka E, El-Zoka AH, Hussein AH, Elbakosh MM, Arafa AK, Ghenghesh KS. Hepatitis B virus and hepatitis C virus in medical waste handlers in Tripoli, Libya. J Hosp Infect 2009; 72(3):258-61; PMID:19443080; http://dx.doi.org/10.1016/j.jhin.2009.03.019
   PubMed Web of Science ®Google Scholar
• Squeri R, La Fauci V, Sindoni L, Cannav∫ G, Ventura Spagnolo E. Study on hepatitis B and C serologic status among municipal solid waste workers in Messina (Italy). J Prev Med Hyg 2006 Sep; 47(3):110-3; PMID:17217188
   PubMedGoogle Scholar
• Dounias G1, Kypraiou E, Rachiotis G, Tsovili E, Kostopoulos S. Prevalence of hepatitis B virus markers in municipal solid waste workers in Keratsini (Greece). Occup Med (Lond) 2005 Jan; 55(1):60-3; PMID:15699092; http://dx.doi.org/10.1093/occmed/kqi007
   PubMed Web of Science ®Google Scholar
• Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S, et al. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat 2013; 20 Suppl 2:1-20; PMID:23827008; http://dx.doi.org/10.1111/jvh.12120
   PubMed Web of Science ®Google Scholar
• Marinho TA, Lopes CL, Teles SA, Matos MA, Matos MA, Kozlowski AG, Oliveira MP, Silva AM, Martins RM. Epidemiology of hepatitis B virus infection among recyclable waste collectors in central Brazil. Rev Soc Bras Med Trop 2014; 47(1):18-23; PMID:24603732; http://dx.doi.org/10.1590/0037-8682-0177-2013
   PubMed Web of Science ®Google Scholar
• Rachiotis G, Papagiannis D, Markas D, Thanasias E, Dounias G, Hadjichristodoulou C. Hepatitis B virus infection and waste collection: prevalence, risk factors, and infection pathway. Am J Ind Med 2012; 55(7):650-5; PMID:22544469; http://dx.doi.org/10.1002/ajim.22057
   PubMed Web of Science ®Google Scholar
• Corrao CR, Del Cimmuto A, Marzuillo C, Paparo E, La Torre G. Association between waste management and HBV among solid municipal waste workers: a systematic review and meta-analysis of observational studies. Scientific World J 2013 Oct 9; 2013:692083; http://dx.doi.org/10.1155/2013/692083
   Web of Science ®Google Scholar
• Hâţu G, Brumboiu MI, Gorgan IN, Bocşan IS. Romanian blood donors screening: is it really necessary and/or mandatory? Rev Med Chir Soc Med Nat Iasi 2013; 117(3):741-6
   PubMedGoogle Scholar
• Scognamiglio P, Girardi E, Fusco M, Piselli P, Spena SR, Maione C, Pisanti FA, Serraino D. Collaborating Study Group. Lack of implementation of Hepatitis B Virus (HBV) vaccination policy in household contacts of HBV carriers in Italy. BMC Infect Dis 2009; 9:86; PMID:19500412; http://dx.doi.org/10.1186/1471-2334-9-86
   PubMed Web of Science ®Google Scholar
• Pitasi MA, Bingham TA, Sey EK, Smith AJ, Teshale EH. Hepatitis B Virus (HBV) Infection, Immunity and Susceptibility Among Men Who Have Sex with Men (MSM), Los Angeles County, USA. AIDS Behav 2013; 18 Suppl 3:248-55
   Google Scholar
• Wang C, Wang Y, Huang X, Li X, Zhang T, Song M, Wu L, Du J, Lu X, Shao S, et al. Prevalence and factors associated with hepatitis B immunization and infection among men who have sex with men in Beijing, China. PLoS One 2012; 7(10):e48219; PMID:23133573; http://dx.doi.org/10.1371/journal.pone.0048219
   PubMed Web of Science ®Google Scholar
• MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, Ford W, LaLota M, Celentano DD, Koblin BA, Torian LV, et al. Young Men's Survey Study Group. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health 2001; 91(6):965-71; PMID:11392942; http://dx.doi.org/10.2105/AJPH.91.6.965
   PubMed Web of Science ®Google Scholar
• Carobene M1, Bolcic F, Farías MS, Quarleri J, Avila MM. HIV, HBV, and HCV molecular epidemiology among trans (transvestites, transsexuals, and transgender) sex workers in Argentina. J Med Virol 2014; 86(1):64-70; PMID:24123155; http://dx.doi.org/10.1002/jmv.23805
   PubMed Web of Science ®Google Scholar
• Johnston LG, Vaillant TC, Dolores Y, Vales HM. HIV, hepatitis B/C and syphilis prevalence and risk behaviors among gay, transsexuals and men who have sex with men, Dominican Republic. Int J STD AIDS 2013; 24(4):313-21; PMID:23970664; http://dx.doi.org/10.1177/0956462412472460
   PubMed Web of Science ®Google Scholar
• Hahné S, van Houdt R, Koedijk F, van Ballegooijen M, Cremer J, Bruisten S, Coutinho R, Boot H. Selective hepatitis B virus vaccination has reduced hepatitis B virus transmission in the Netherlands. PLoS One 2013 Jul 29; 8(7):e67866; http://dx.doi.org/10.1371/journal.pone.0067866
   PubMed Web of Science ®Google Scholar
• Taketa K, Ikeda S, Suganuma N, Phornphutkul K, Peerakome S, Sitvacharanum K, Jittiwutikarn J. Differential seroprevalences of hepatitis C virus, hepatitis B virus and human immunodeficiency virus among intravenous drug users, commercial sex workers and patients with sexually transmitted diseases in Chiang Mai, Thailand. Hepatol Res 2003; 27(1):6-12; PMID:12957200; http://dx.doi.org/10.1016/S1386-6346(03)00163-3
   PubMed Web of Science ®Google Scholar
• Schuelter-Trevisol F, Custódio G, Silva AC, Oliveira MB, Wolfart A, Trevisol DJ. HIV, hepatitis B and C, and syphilis prevalence and coinfection among sex workers in Southern Brazil. Rev Soc Bras Med Trop 2013; 46(4):493-7; PMID:23681430; http://dx.doi.org/10.1590/0037-8682-1364-2013
   PubMed Web of Science ®Google Scholar
• Praseeda SD, Anuradha D, Jayanthi SS. A Study on the HBV and the HCV Infections in Female Sex Workers and their Co-Infection with HIV. J Clin Diagn Res 2013; 7(2):234-7; PMID:23543505
   PubMedGoogle Scholar
• Kassak K, Mahfoud Z, Kreidieh K, Shamra S, Afifi R, Ramia S. Hepatitis B virus and hepatitis C virus infections among female sex workers and men who have sex with men in Lebanon: prevalence, risk behaviour and immune status. Sex Health 2011 Jun; 8(2):229-33; PMID:21592438; http://dx.doi.org/10.1071/SH10080
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidance on Prevention of Viral Hepatitis B and C Among People Who Inject Drugs. Geneva, 2012 Jul. Available from: http://www.ncbi.nlm.nih.gov/books/NBK144127/
   Google Scholar
• Walsh N, Verster A, Rodolph M, Akl EA. WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. Int J Drug Policy 2014; S0955-3959(14):00012-7
   Google Scholar
• Arama V, Leblebicioglu H, Simon K, Zarski JP, Niederau C, Habersetzer F, Vermehren J, Bludzin W, Jinga M, Ulusoy S, et al. the AI; European Longitudinal Chronic Hepatitis B Study Group. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther 2013; 19(3):245-57
   PubMed Web of Science ®Google Scholar
• Owusu-Edusei K, Jr, Chesson HW, Gift TL, Tao G, Mahajan R, Ocfemia MC, Kent CK. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013; 40(3):197-201; PMID:23403600; http://dx.doi.org/10.1097/OLQ.0b013e318285c6d2
   PubMed Web of Science ®Google Scholar
• Marcellin P, Arama V, Leblebicioglu H, Zarski JP, Zeuzem S, Mauss S, Sieklucki J, Acalovschi M, Usluer G, Klauck I, et al. the AI; Longitudinal Study Group. Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study. Antivir Ther 2013; 19(3):235-43; PMID:23574686
   PubMed Web of Science ®Google Scholar
• Lu J, Xu A, Wang J, Zhang L, Song L, Li R, Zhang S, Zhuang G, Lu M. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res 2013; 13:37; PMID:23368750; http://dx.doi.org/10.1186/1472-6963-13-37
   PubMed Web of Science ®Google Scholar
• Colombo GL, Gaeta GB, Vigan∫ M, Di Matteo S. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res 2011; 3:37-46; PMID:21935331; http://dx.doi.org/10.2147/CEOR.S16655
   PubMedGoogle Scholar
• Yang BM, Kim DJ, Byun KS, Kim HS, Park JW, Shin S. The societal burden of HBV-related disease: South Korea. Dig Dis Sci 2010; 55(3):784-93; PMID:19333757; http://dx.doi.org/10.1007/s10620-009-0786-4
   PubMed Web of Science ®Google Scholar
• Yang BM, Kim CH, Kim JY. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol 2004; 38(10 Suppl 3):S153-7; PMID:15602164; http://dx.doi.org/10.1097/00004836-200411003-00007
   PubMed Web of Science ®Google Scholar
• Ong SC, Lim SG, Li SC. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. J Viral Hepat 2009; 16(1):53-63; PMID:19192158; http://dx.doi.org/10.1111/j.1365-2893.2008.01042.x
   PubMed Web of Science ®Google Scholar
• Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 2004; 38(10 Suppl 3):S148-52; PMID:15602163; http://dx.doi.org/10.1097/00004836-200411003-00006
   PubMed Web of Science ®Google Scholar
• Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004; 38(10 Suppl 3):S144-7; PMID:15602162; http://dx.doi.org/10.1097/00004836-200411003-00005
   PubMed Web of Science ®Google Scholar
• Butler JR, Pianko S, Korda RJ, Nguyen S, Gow PJ, Roberts SK, Strasser SI, Sievert W. The direct cost of managing patients with chronic hepatitis B infection in Australia. J Clin Gastroenterol 2004; 38(10 Suppl 3):S187-92; PMID:15602169; http://dx.doi.org/10.1097/00004836-200411003-00012
   PubMed Web of Science ®Google Scholar
• Arnold E, Yuan Y, Iloeje U, Cook G. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Appl Health Econ Health Policy 2008; 6(4):231-46; PMID:19382822; http://dx.doi.org/10.1007/BF03256136
   PubMedGoogle Scholar
• Gagnon YM, Levy AR, Iloeje UH, Briggs AH. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 2004; 38(10 Suppl 3):S179-86; PMID:15602168; http://dx.doi.org/10.1097/00004836-200411003-00011
   PubMed Web of Science ®Google Scholar
• Kalantari H, Davari M, Akbari M, Hejazi SM, Kalantari M, Zakerin S, Shahshahan Z. The estimation of direct medical costs of treating patients with chronic hepatitis B and C in Iran. Int J Prev Med 2012; 3(3):191-6; PMID:22448312
   PubMedGoogle Scholar
• Hu M, Chen W. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health 2009; 12 Suppl 3:S89-92; PMID:20586991; http://dx.doi.org/10.1111/j.1524-4733.2009.00636.x
   PubMedGoogle Scholar
• Zhiqiang G, Zhaohui D, Qinhuan W, Dexian C, Yunyun F, Hongtao L, Iloeje UH. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004; 38(10 Suppl 3):S175-8; PMID:15602167; http://dx.doi.org/10.1097/00004836-200411003-00010
   PubMed Web of Science ®Google Scholar
• Wiens A, Lenzi L, Venson R, Pedroso ML, Correr CJ, Pontarolo R. Economic evaluation of treatments for chronic hepatitis B. Braz J Infect Dis 2013; 17(4):418-26; PMID:23849851; http://dx.doi.org/10.1016/j.bjid.2012.12.005
   PubMed Web of Science ®Google Scholar
• Park JY, Heo J, Lee TJ, Yim HJ, Yeon JE, Lim YS, Seo MJ, Ahn SH, Lee MS. A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PLoS One 2013; 8(3):e57900; PMID:23536775; http://dx.doi.org/10.1371/journal.pone.0057900
   PubMed Web of Science ®Google Scholar
• Hulstaert F, Schwierz C, Nevens F, Thiry N, Gamil M, Colle I, Van de Sande S, Horsmans Y. Should chronic hepatitis B be treated as early as possible? Int J Technol Assess Health Care 2013; 29(1):35-41;; PMID:23298548; http://dx.doi.org/10.1017/S0266462312000736
   PubMed Web of Science ®Google Scholar
• Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: comparison of current treatment guidelines. World J Gastroenterol 2012; 18(42):6106-13;; PMID:23155339; http://dx.doi.org/10.3748/wjg.v18.i42.6106
   PubMed Web of Science ®Google Scholar
• He J, Bowen JM, Xie F, Goeree R. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. Value Health 2012; 15(6):894-906; PMID:22999140; http://dx.doi.org/10.1016/j.jval.2012.06.005
   PubMed Web of Science ®Google Scholar
• Husic-Selimovic A, Vukobrat-Bijedic Z, Bevanda M, Mesihovic R, Zerem E, Ahmetagic S, Trbojevic S, Verhaz A, Kezic Z, Zildzic M, et al. Associations of gastroenterology and hepatology of Bosnia and Herzegovina. Diagnosis and treatment of chronic viral hepatitis B and C: doctrinary approach. Med Arh 2012; 66(3 Suppl 1):56-69; http://dx.doi.org/10.5455/medarh.2012.66.s56-s68
   Google Scholar
• Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, et al. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012; 13(5):663-76; PMID:22815098; http://dx.doi.org/10.1007/s10198-012-0413-8
   PubMed Web of Science ®Google Scholar
• La Torre G, de Waure C, Chiaradia G, Mannocci A, Capri S, Ricciardi W. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy. Vaccine 2010; 28(19):3379-84; PMID:20197141; http://dx.doi.org/10.1016/j.vaccine.2010.02.080
   PubMed Web of Science ®Google Scholar
• Ricciardi W, Dirodi B, Bonanni P, Capri S, Castiglia P, Gabutti G, Gasparini R, Giorgi Rossi P, Grilli G, La Torre G. Methodological aspects of clinical and economic impact of vaccine interventions and HTA. Focus on HPV vaccination. Ann Ig 2011; 23(5):419-34; PMID:22403995
   PubMedGoogle Scholar
• La Torre G, de Waure C, Chiaradia G, Mannocci A, Capri S, Bamfi F, Ricciardi W. Guidance for future HTA applications to vaccines: the HPV lesson. Hum Vaccin 2011; 7(9):900-4; PMID:21865880; http://dx.doi.org/10.4161/hv.7.9.16084
   PubMed Web of Science ®Google Scholar
• Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7(35):iii-iv, xi-xiii, 1-170; http://dx.doi.org/10.3310/hta7350
   Google Scholar
• Sehatzadeh S. Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review. Ont Health Technol Assess Ser 2012; 12(3):1-64
   Google Scholar
• La Torre G, de Waure C, Chiaradia G, Mannocci A, Specchia ML, Nicolotti N, Ricciardi W. The future of best investing in vaccines: the Health Technology Assessment approach. Vaccine 2008; 26(13):1609-10; PMID:18289744; http://dx.doi.org/10.1016/j.vaccine.2008.01.009
   PubMed Web of Science ®Google Scholar
• Chalkidou K, Marten R, Cutler D, Culyer T, Smith R, Teerawattananon Y, Cluzeau F, Li R, Sullivan R, Huang Y, et al. Health technology assessment in universal health coverage. Lancet 2013; 382(9910):e48-9; PMID:24360390; http://dx.doi.org/10.1016/S0140-6736(13)62559-3
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ital J Public Health 2009; 4:94-131
   Google Scholar
• La Torre G, Nicolotti N, De Waure C, Ricciardi W. Development of a weighted scale to assess the quality of cost-eectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine. J Public Health (Springer) 2010; 19 (2):103-11; http://dx.doi.org/10.1007/s10389-010-0377-z
   Google Scholar